ALXN - Alexion Pharmaceuticals expects to exceed top end of revenue guidance

Alexion Pharmaceuticals ([[ALXN]] -0.2%) expects to exceed the high end of the company’s 2020 revenue guidance of $5.9B-5.95B that was previously provided by the company in connection with its Q3 financial results.Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020.Company continues to expand into additional therapeutic areas, with a pipeline of more than 20 development programs across seven rare disease franchises.The company has the ambition to deliver double-digit topline growth through 2025, targeting $9B-10B in global revenue.Quick look at the company's developmental pipeline.Previously: Apellis remains a top pick at Baird after AstraZeneca/Alexion deal (Dec. 14, 2020)

For further details see:

Alexion Pharmaceuticals expects to exceed top end of revenue guidance